文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

前脑啡肽A 119-159对重症急性肾损伤患者脱离肾脏替代治疗的评估:一项外部多中心先导研究

Evaluation of Proenkephalin A 119-159 for liberation from renal replacement therapy: an external, multicenter pilot study in critically ill patients with acute kidney injury.
PubMed 文献 · Crit Care · 2023-07-10
一句话结论多中心验证显示CRRT启动时penKid低值与成功脱离CRRT无关,第3天低penKid与成功脱离相关(sHR 2.35),但预测能力不及高每日尿量(sHR 2.91)。

本研究利用RICH试验的数据和血浆样本,在重症急性肾损伤患者中外部验证血浆前脑啡肽A 119-159(penKid)与成功脱离连续性肾脏替代治疗(CRRT)的关联。以100 pmol/l为界将患者分为低和高penKid组,采用竞争风险时间-事件分析。结果显示CRRT启动时低penKid与早期成功脱离CRRT无关(sHR 1.01,95%CI 0.73-1.40,p=0.945);但CRRT第3天低penKid与成功脱离相关(sHR 2.35,95%CI 1.45-3.81,p<0.001),高penKid与不成功脱离相关(sHR 0.46,95%CI 0.26-0.80,p=0.007)。高每日尿量(>436 ml/d)与成功脱离的关联更强(sHR 2.91,95%CI 1.80-4.73,p<0.001)。作者认为penKid可能是监测CRRT期间肾功能恢复的生物标志物,但被高每日尿量超越,研究结果需在前瞻性研究或随机对照试验中进一步评估。

要点

  • CRRT启动时低penKid(≤100 pmol/l)与早期成功脱离CRRT无关(sHR 1.01,95%CI 0.73-1.40,p=0.945)。
  • CRRT第3天低penKid与成功脱离CRRT相关(sHR 2.35,95%CI 1.45-3.81,p<0.001)。
  • CRRT第3天高penKid与不成功脱离相关(sHR 0.46,95%CI 0.26-0.80,p=0.007)。
  • 高每日尿量(>436 ml/d)与成功脱离CRRT的关联强于penKid(sHR 2.91,95%CI 1.80-4.73,p<0.001)。
  • 作者认为penKid可能是监测CRRT期间肾功能恢复的生物标志物,但需前瞻性研究或随机对照试验进一步评估。

适用人群与场景

  • 重症急性肾损伤患者,数据来自RICH试验(Effect of Regional Citrate Anticoagulation versus Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury-A Randomized Clinical Trial)的受试者。

诊断标准与关键阈值

  • 以血浆penKid 100 pmol/l为界,将患者分为低penKid组和高penKid组。
  • 竞争风险终点:成功脱离CRRT;不成功脱离CRRT定义为死亡或停止主要CRRT后一周内启动新的肾脏替代治疗。

研究设计与关键结果

  • 研究类型:外部、多中心先导验证研究,使用RICH试验的数据和血浆样本。
  • penKid在CRRT启动时和CRRT第3天所有可用的血浆样本中检测。
  • CRRT启动时低penKid与高penKid相比,与早期成功脱离CRRT无关(sHR 1.01,95%CI 0.73-1.40,p=0.945)。
  • CRRT第3天标志点分析显示低penKid与成功脱离CRRT相关(sHR 2.35,95%CI 1.45-3.81,p<0.001)。
  • CRRT第3天高penKid与不成功脱离相关(sHR 0.46,95%CI 0.26-0.80,p=0.007)。
  • 高每日尿量(>436 ml/d)与成功脱离CRRT的关联更强(sHR 2.91,95%CI 1.80-4.73,p<0.001),优于penKid。
  • RICH试验注册于clinicaltrials.gov:NCT02669589,注册日期2016年2月1日。

证据类型、等级与局限

  • 证据类型:基于随机对照试验(RICH试验)数据的外部多中心先导验证研究。
  • 局限:作者指出这些探索性结果来自单中心试验,需要外部多中心队列验证;本研究结果需在前瞻性研究或随机对照试验中进一步评估。

对床旁实践的改变

  • 作者认为penKid可能是监测CRRT期间肾功能恢复的生物标志物,但被高每日尿量超越,尚需前瞻性研究或随机对照试验进一步评估。

指南或共识出处

  • RICH试验:Effect of Regional Citrate Anticoagulation versus Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury-A Randomized Clinical Trial,注册号NCT02669589。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Recent evidence suggests an association of plasma Proenkephalin A 119-159 (penKid) with early and successful liberation from continuous renal replacement therapy (CRRT) in critically ill patients with acute kidney injury. However, these exploratory results are derived from a monocentric trial and therefore require external validation in a multicenter cohort.

METHODS: Data and plasma samples from the "Effect of Regional Citrate Anticoagulation versus Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury-A Randomized Clinical Trial" (RICH Trial) were used for this validation study. PenKid was measured in all plasma samples available at CRRT initiation and at day 3 of CRRT. Patients were categorized into low and high penKid groups with a cutoff at 100 pmol/l. Competing-risk time-to-event analyses were performed. Competing risk endpoints were successful and unsuccessful liberation from CRRT, the latter meaning death or initiation of a new RRT within one week of discontinuation of primary CRRT. Then penKid was compared to urinary output.

RESULTS: Low pre-CRRT penKid levels at CRRT initiation were not associated with early and successful liberation from CRRT compared to patients with high pre-CRRT penKid levels [subdistribution hazard ratio (sHR) 1.01, 95% CI 0.73-1.40, p = 0.945]. However, the landmark analysis on day 3 of ongoing CRRT demonstrated an association between low penKid levels and successful liberation from CRRT (sHR 2.35, 95% CI 1.45-3.81, p < 0.001) and an association between high penKid levels and unsuccessful liberation (sHR 0.46, 95% CI 0.26-0.80, p = 0.007). High daily urinary output (> 436 ml/d) was even stronger associated with successful liberation (sHR 2.91, 95% CI 1.80-4.73, p < 0.001) compared to penKid.

DISCUSSION: This study suggests that penKid may be a competent biomarker to monitor the recovery of kidney function during CRRT. This is in line with previous findings and investigated this concept in a multicenter cohort. Again, low penKid was associated with early and successful CRRT liberation, but was outperformed by high daily urinary output. The findings of this study now warrant further evaluation in prospective studies or a randomized controlled trial. Trial registration The RICH Trial was registered at clinicaltrials.gov: NCT02669589. Registered 01 February 2016.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. von Groote T, Albert F, Meersch M, et al. Evaluation of Proenkephalin A 119-159 for liberation from renal replacement therapy: an external, multicenter pilot study in critically ill patients with acute kidney injury. Crit Care. 2023. PMID: 37430375. doi:10.1186/s13054-023-04556-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。